Citius Oncology, Inc. (CTOR) 10-Year Financial Performance & Capital Metrics

CTOR • • Industrial / General

HealthcareLarge PharmaEarly-Stage & Niche DevelopersClinical-Stage Pain & Specialty Developers

AboutCitius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.Show more

Revenue $0
EBITDA -$23M -14.2%
Net Income -$25M -17.1%
EPS (Diluted) -0.34 -13.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -54.42% +7.8%
ROIC -37.27% +8.9%
Debt/Equity 0.08 +2.8%
Interest Coverage -107.89

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak momentum: RS Rating 11 (bottom 11%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM-13.27%

ROCE

10Y Avg-37.37%

5Y Avg-37.37%

3Y Avg-45.43%

Latest-45.62%

Peer Comparison

Clinical-Stage Pain & Specialty Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SRXHSRx Health Solutions Inc.	13.22M	0.19	-0.21	28.4%	-9.36%		11.92%
SCLXScilex Holding Company	80.6M	11.46	-0.59	21.07%	-9.31%		24.01%
MIRAMIRA Pharmaceuticals, Inc.	61.14M	1.46	-2.86			-376.4%
CTORCitius Oncology, Inc.	91.58M	1.08	-3.18			-55.19%		0.08

Profit & Loss

	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	4.86M	12.12M	20.57M	23.52M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	1.43M	7.88M	15.65M	17.1M
SG&A % of Revenue	-	-	-	-
Research & Development	3.43M	4.24M	4.92M	6.42M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-4.86M	-12.12M	-20.57M	-23.52M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	-1.5%	-0.7%	-0.14%
EBITDA+	-4.86M	-12.12M	-20.57M	-23.49M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	-1.5%	-0.7%	-0.14%
D&A (Non-Cash Add-back)	0	0	0	0
EBIT	-4.86M	-12.12M	-20.57M	-23.49M
Net Interest Income+	493.02K	3.43M	0	-181.66K
Interest Income	493.02K	3.43M	0	36.37K
Interest Expense	0	0	0	218.03K
Other Income/Expense	0	0	0	-181.66K
Pretax Income+	-4.86M	-12.12M	-20.57M	-23.7M
Pretax Margin %	-	-	-	-
Income Tax+	576K	576K	576K	1.06M
Effective Tax Rate %	1.12%	1.05%	1.03%	1.04%
Net Income+	-5.43M	-12.7M	-21.15M	-24.76M
Net Margin %	-	-	-	-
Net Income Growth %	-	-1.34%	-0.67%	-0.17%
Net Income (Continuing)	-5.43M	-12.7M	-21.15M	-24.76M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.08	-0.19	-0.30	-0.34
EPS Growth %	-	-1.49%	-0.58%	-0.13%
EPS (Basic)	-0.08	-0.19	-0.30	-0.34
Diluted Shares Outstanding	90.16M	89.48M	71.55M	73.27M
Basic Shares Outstanding	90.16M	89.48M	71.55M	73.27M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	2.69M	7.73M	10.97M	27.54M
Cash & Short-Term Investments	0	0	112	3.92M
Cash Only	289.18K	26.52K	112	3.92M
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	8.27M	22.29M
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	0	0	0
Total Non-Current Assets+	40M	40M	73.4M	73.4M
Property, Plant & Equipment	0	0	0	0
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	40M	40M	73.4M	73.4M
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	0	0
Total Assets+	42.69M	47.73M	84.37M	100.94M
Asset Turnover	-	-	-	-
Asset Growth %	-	0.12%	0.77%	0.2%
Total Current Liabilities+	5.85M	21.05M	32.7M	49.49M
Accounts Payable	92.31K	1.29M	3.71M	13.23M
Days Payables Outstanding	-	-	-	-
Short-Term Debt	0	0	0	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	0	-588.8K	0
Current Ratio	0.46x	0.37x	0.34x	0.56x
Quick Ratio	0.46x	0.37x	0.08x	0.11x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	576K	1.15M	5.53M	6.59M
Long-Term Debt	0	0	3.8M	3.8M
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	576K	1.15M	1.73M	2.78M
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	6.42M	22.2M	38.23M	56.08M
Total Debt+	0	0	3.8M	3.8M
Net Debt	-289.18K	-26.52K	3.8M	-124.8K
Debt / Equity	-	-	0.08x	0.08x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-	-	-	-107.89x
Total Equity+	36.27M	25.54M	46.14M	44.87M
Equity Growth %	-	-0.3%	0.81%	-0.03%
Book Value per Share	0.40	0.29	0.64	0.61
Total Shareholders' Equity	36.27M	25.54M	46.14M	44.87M
Common Stock	6.75K	6.75K	7.16K	8.35K
Retained Earnings	-5.43M	-18.13M	-39.28M	-64.04M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	-47.97K	-601.3K	126.35K	-5.49M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-11.54%	1.21%	-44.47%
Net Income	-5.43M	-12.7M	-21.15M	-24.76M
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	0	1.97M	7.5M	8.32M
Deferred Taxes	576K	576K	576K	1.06M
Other Non-Cash Items	-47.97K	-601.3K	0	0
Working Capital Changes	4.86M	10.16M	13.2M	9.89M
Change in Receivables	25.99K	349.05K	0	0
Change in Inventory	0	0	-2.13M	-12.65M
Change in Payables	92.31K	1.2M	2.42M	9.52M
Cash from Investing+	-67.32M	-1.32M	-5M	-5.75M
Capital Expenditures	0	0	0	-5.75M
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	-5M	0
Cash from Financing+	67.66M	1.66M	4.87M	15.17M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	-383.84K	1.66M	1.07M	0
Net Change in Cash	-	-	-	-
Free Cash Flow+	-47.97K	-601.3K	-4.87M	-11.24M
FCF Margin %	-	-	-	-
FCF Growth %	-	-11.53%	-7.11%	-1.31%
FCF per Share	-0.00	-0.01	-0.07	-0.15
FCF Conversion (FCF/Net Income)	0.01x	0.05x	-0.01x	0.22x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2022	2023	2024	2025
Return on Equity (ROE)	-14.98%	-41.09%	-59.01%	-54.42%
Return on Invested Capital (ROIC)	-10.12%	-29.57%	-40.9%	-37.27%
Debt / Equity	-	-	0.08x	0.08x
Interest Coverage	-	-	-	-107.89x
FCF Conversion	0.01x	0.05x	-0.01x	0.22x

Frequently Asked Questions

Growth & Financials

Citius Oncology, Inc. (CTOR) grew revenue by 0.0% over the past year. Growth has been modest.

Citius Oncology, Inc. (CTOR) reported a net loss of $24.8M for fiscal year 2025.

Dividend & Returns

Citius Oncology, Inc. (CTOR) has a return on equity (ROE) of -54.4%. Negative ROE indicates the company is unprofitable.

Citius Oncology, Inc. (CTOR) had negative free cash flow of $5.5M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener